Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-7-19
pubmed:abstractText
T cell effector functions contribute to the pathogenesis of rheumatoid arthritis. PKC-theta transduces the signal from the TCR through activation of transcription factors NF-kappaB, AP-1, and NFAT. We examined the effects of PKC-theta deficiency on two Th1-dependent models of Ag-induced arthritis and found that PKC-theta-deficient mice develop disease, but at a significantly diminished severity compared with wild-type mice. In the methylated BSA model, cellular infiltrates and articular cartilage damage were mild in the PKC-theta-deficient mice as compared with wild-type mice. Quantitation of histopathology reveals 63 and 77% reduction in overall joint destruction in two independent experiments. In the type II collagen-induced arthritis model, we observed a significant reduction in clinical scores (p < 0.01) in three independent experiments and diminished joint pathology (p < 0.005) in PKC-theta-deficient compared with wild-type littermates. Microcomputerized tomographic imaging revealed that PKC-theta deficiency also protects from bone destruction. PKC-theta-deficient CD4(+) T cells show an impaired proliferative response, decreased intracellular levels of the cytokines IFN-gamma, IL-2, and IL-4, and significantly diminished cell surface expression of the activation markers CD25, CD69, and CD134/OX40 on memory T cells. We demonstrate decreased T-bet expression and significantly reduced IgG1 and IgG2a anti-collagen II Ab levels in PKC-theta-deficient mice. Collectively, our results demonstrate that PKC-theta deficiency results in an attenuated response to Ag-induced arthritis, which is likely mediated by the reduced T cell proliferation, Th1/Th2 cell differentiation and T cell activation before and during disease peak.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
177
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1886-93
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16849501-Animals, pubmed-meshheading:16849501-Antigens, pubmed-meshheading:16849501-Arthritis, Experimental, pubmed-meshheading:16849501-Autoantibodies, pubmed-meshheading:16849501-Cell Movement, pubmed-meshheading:16849501-Cell Proliferation, pubmed-meshheading:16849501-Collagen, pubmed-meshheading:16849501-Down-Regulation, pubmed-meshheading:16849501-Female, pubmed-meshheading:16849501-Immunophenotyping, pubmed-meshheading:16849501-Isoenzymes, pubmed-meshheading:16849501-Male, pubmed-meshheading:16849501-Mice, pubmed-meshheading:16849501-Mice, Inbred C57BL, pubmed-meshheading:16849501-Mice, Inbred DBA, pubmed-meshheading:16849501-Mice, Knockout, pubmed-meshheading:16849501-Protein Kinase C, pubmed-meshheading:16849501-Serum Albumin, Bovine, pubmed-meshheading:16849501-T-Box Domain Proteins, pubmed-meshheading:16849501-T-Lymphocytes, pubmed-meshheading:16849501-Th1 Cells, pubmed-meshheading:16849501-Transcription Factors, pubmed-meshheading:16849501-Up-Regulation
pubmed:year
2006
pubmed:articleTitle
PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis.
pubmed:affiliation
Inflammation Department, Millennium Pharmaceuticals, Cambridge, MA 02139, USA. ahealy@momentapharma.com
pubmed:publicationType
Journal Article